| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |
|
Medicine details |
|
| Medicine name | nivolumab/ipilimumab (Opdivo®/Yervoy®) |
| Formulation | 10 mg/mL concentrate for solution for infusion, 5 mg/ml concentrate for solution for infusion |
| Reference number | 2827 |
| Indication | First-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 10/12/2018 |
| NICE guidance | TA780: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma |